Tagged with Lilly

Puerto Rico Puerto Rico’s close-knit pharmaceutical sector is aiming to attract new talent to the industry so as to further increase its global competitiveness.   There is a strong, robust ecosystem around the pharmaceutical industry on the island and we are looking to attract the new generation to work in it Wendy…

Puerto Rico With more than 50 years of experience in pharmaceutical manufacturing, Puerto Rico is today a manufacturing base for 11 of the world’s 20 largest pharmaceutical and biopharmaceutical companies. However, considering its economic struggles and rising competition both from US states and international manufacturing hubs such as Ireland and Singapore, the…

China Julio Gay-Ger, an industry and Eli Lilly veteran, shares how he is leveraging on his 23 years of experience managing Lilly affiliates in LATAM to deliver on Lilly’s objective to position China as the second-largest affiliate for the Group; the significance of their recent February 2019 launch of diabetes treatment…

Spain Nabil Daoud, president of Lilly Spain, Portugal and Greece, highlights the importance of Lilly’s Spanish operations to the global group; Spain being the only country outside to hold manufacturing, pre-clinical research and commercial sales functionalities. Furthermore, he gives insight into his strategy to deliver the company’s exciting pipeline and his…

Korea Paul Henry Huibers, president of Lilly Korea discusses Lilly’s strong double-digit growth following a challenging period of restructuring. Huibers offers his opinion on the pricing difficulties within the Korean market, emphasizing the importance of volume over price. He also concludes that Korea should focus on establishing itself as a leader…

Algeria Doria Oughlis, Lilly’s GM for North West Africa, outlines the company’s historic presence in Algeria, current priorities and Lilly’s overarching contribution to the health of the region.   Could you please start by describing Lilly’s legacy in Algeria to date? Lilly’s presence in Algeria actually long predates the setting up…

Algeria Multinational pharmaceutical companies are increasingly choosing Algeria as a base for their regional headquarters, despite the complexities of the local market. The representatives of Lilly, bioMérieux and Abbott in Algeria tell us why. As geographically the largest country in Africa, Algeria stands out, as does its universal healthcare system which bears…

Portugal Antonio Leão discusses Lilly Portugal’s sustained growth record in recent years, its ambition to introduce two new innovative treatments to the market every year until 2022, and their empowering approach when tackling market access hurdles. In suggesting improvements to the predictability of the pharmaceutical framework, Leão, soon to reach 30…

India Luca Visini, the recently appointed managing director of Eli Lilly & Company for India, shares with us his first perspective of the Indian ecosystem He also provides insights into some of his key objectives in India, which include consolidating the reputation of Eli Lilly as a key stakeholder in the…

Singapore Eli Lilly and Company General Manager of South ASEAN, Dr. Faiz Ansari speaks about the expanded scope of his role,  Lilly’s pipeline, and the approach that Lilly has taken to support healthcare delivery and improve patients‘ access to treatment and to support programs in a region that is so inherently…

Ireland Deirdre Bourke, Country Lead at Eli Lilly’s Irish affiliate, highlights the strategic importance of Ireland to Lilly’s global operations, their exciting upcoming pipeline, the challenges and opportunities she foresees for Lilly in Ireland, and her own professional transition from managing Lilly’s diabetes portfolio to Lilly’s overall commercial activities in Ireland.…

Switzerland Michael Cobas Meyer of Eli Lilly Switzerland reveals how these are very exciting times for the company, particularly given an extremely rich pipeline in the areas of diabetes, oncology and bio-medicines; how the challenge will be to transition from their existing portfolio to new products; and why Lilly´s focus is…